Soleno Therapeutics (SLNO) Reaches $0.40 1 Year Low; Blue Martini Software (BLUE) Sentiment Is 1.29

August 4, 2017 - By Vivian Currie

The stock of Soleno Therapeutics Inc (NASDAQ:SLNO) hit a new 52-week low and has $0.39 target or 3.00% below today’s $0.40 share price. The 5 months bearish chart indicates high risk for the $19.13 million company. The 1-year low was reported on Aug, 4 by Barchart.com. If the $0.39 price target is reached, the company will be worth $573,900 less. About 88,327 shares traded or 10.99% up from the average. Soleno Therapeutics Inc (NASDAQ:SLNO) has 0.00% since August 4, 2016 and is . It has underperformed by 16.70% the S&P500.

bluebird bio, Inc. is a clinical-stage biotechnology company. The company has market cap of $4.25 billion. The Firm is focused on developing gene therapies for severe diseases and cancer. It currently has negative earnings. With its lentiviral gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas.

Ratings analysis reveals 50% of Bluebirdbio’s analysts are positive. Out of 4 Wall Street analysts rating Bluebirdbio, 2 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $80.0 while the high is $87.0. The stock’s average target of $83.50 is -12.17% below today’s ($95.07) share price. BLUE was included in 4 notes of analysts from October 14, 2016. On Friday, October 14 the stock rating was maintained by Leerink Swann with “Outperform”. The firm earned “Buy” rating on Thursday, December 1 by Maxim Group. The firm has “Neutral” rating by Roth Capital given on Monday, February 6. On Friday, October 14 the stock rating was downgraded by Cantor Fitzgerald to “Sell”.

About 387,419 shares traded. bluebird bio Inc (BLUE) has risen 112.34% since August 4, 2016 and is uptrending. It has outperformed by 95.64% the S&P500.

Eventide Asset Management Llc holds 2.36% of its portfolio in bluebird bio Inc for 587,677 shares. First Light Asset Management Llc owns 71,246 shares or 1.93% of their US portfolio. Moreover, Deerfield Management Co has 0.77% invested in the company for 302,027 shares. The New York-based Armistice Capital Llc has invested 0.58% in the stock. Artal Group S.A., a Luxembourg-based fund reported 422,536 shares.

Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare firm that develops and commercializes neonatology devices and diagnostics. The company has market cap of $19.13 million. The Firm also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. It currently has negative earnings. The Firm offers products, such as CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief.